Table 4.
Endoscopy indication and symptoms of individuals with serrated polyps according to Swedish histopathology reports
| Variable | HP | TSA | SSA/P | U | F | Total | |||
|---|---|---|---|---|---|---|---|---|---|
| SSA/P | SA | Mixed | Total | ||||||
| INDIVIDUALS | 34 (32%) | 3 (3%) | 8 (8%) | 51 (48%) | 12 (11%) | 70 (66%) | 3 (3%) | 5 (5%) | 106 (100%) |
| Indication | |||||||||
| Symptomatic | 18 (53%) | 1 (33%) | 3 (38%) | 35 (69%) | 8 (67%) | 45 (64%) | 1 (33%) | 4 (80%) | 64 (60%) |
| Non-symptomatic* | 15 (44%) | 2 (67%) | 5 (63%) | 14 (27%) | 4 (33%) | 23 (33%) | 2 (67%) | 1 (20%) | 39 (37%) |
| Unspecified | 1 (3%) | 0 (0%) | 0 (0%) | 2 (4%) | 0 (0%) | 2 (3%) | 0 (0%) | 0 (0%) | 3 (3%) |
| Symptoms | |||||||||
| Change in stool form | 16 (47%) | 1 (33%) | 2 (25%) | 23 (45%) | 5 (42%) | 30 (43%) | 0 (0%) | 2 (40%) | 47 (44%) |
| Change in stool colour | 9 (26%) | 0 (0%) | 3 (38%) | 22 (43%) | 3 (25%) | 27 (39%) | 1 (33%) | 1 (20%) | 36 (34%) |
| Abdominal pain | 5 (15%) | 0 (0%) | 4 (50%) | 10 (20%) | 2 (17%) | 15 (21%) | 1 (33%) | 1 (20%) | 22 (21%) |
| Weight loss | 2 (6%) | 0 (0%) | 0 (0%) | 6 (12%) | 1 (8%) | 7 (10%) | 1 (33%) | 0 (0%) | 9 (8%) |
| Fatigue | 2 (6%) | 0 (0%) | 0 (0%) | 4 (8%) | 2 (17%) | 6 (9%) | 0 (0%) | 0 (0%) | 8 (8%) |
| Anaemia | 6 (18%) | 0 (0%) | 1 (13%) | 18 (35%) | 4 (33%) | 22 (31%) | 1 (33%) | 2 (40%) | 30 (28%) |
| Positive FOBT | 4 (12%) | 3 (100%) | 1 (13%) | 4 (8%) | 3 (25%) | 8 (11%) | 2 (67%) | 0 (0%) | 15 (14%) |
| Others§ | 4 (12%) | 0 (0%) | 0 (0%) | 5 (10%) | 0 (0%) | 5 (7%) | 0 (0%) | 0 (0%) | 8 (8%) |
Abbreviations: F = False positive serrated polyp; FOBT = Faecal occult blood test; HP = Hyperplastic polyp; SA = Serrated adenoma; SSA/P = Sessile serrated adenoma/polyp; TSA = Traditional serrated adenoma; U = Unspecified serrated polyp. *Polyp surveillance, CRC screening, etc., §Fever, burning, nausea, etc.